Table 7 Mean scores (± SD) of EORTC QLQ-NMIBC24 subscales at 6 weeks after diagnosis for 541 NMIBC patients participating in UroLife by risk category (known group validity)
Patient score, mean (SD) | Effect sizea | ||||
|---|---|---|---|---|---|
Low risk (N = 99) | Intermediate risk (N = 250) | High risk (N = 192) | Intermediate vs. low | High vs. low | |
Urinary symptoms (–)d | 24.5 (20.8) | 26.3 (20.1) | 33.1 (21.3) | 0.09 | 0.41c |
Malaise (–)d | 2.4 (10.8) | 3.7 (13.7) | 4.3 (10.4) | 0.11 | 0.18 |
Future worries (–)d | 28.4 (20.8) | 30.6 (24.1) | 40.1 (24.5) | 0.10 | 0.51c |
Bloating and flatulence (–)d | 21.6 (23.2) | 15.4 (20.5) | 17.8 (20.8) | − 0.28b | − 0.17 |
Sexual functioning (+)d | 23.3 (22.3) | 21.5 (22.9) | 21.7 (22.4) | − 0.08 | − 0.07 |
Male sexual problems (–)d | 30.9 (30.1) | 26.5 (33.1) | 29.1 (33.1) | − 0.14 | − 0.07 |
Intravesical treatment issues (–)d | 9.9 (17.6) | 8.0 (17.9) | 12.7 (20.4) | − 0.11 | 0.15 |
Sexual intimacy (–)d | 9.2 (19.3) | 12.1 (21.7) | 18.2 (24.2) | 0.14 | 0.41b |
Risk of contaminating partner (–)d | 9.7 (21.7) | 15.5 (22.8) | 29.1 (31.3) | 0.26 | 0.72c |
Sexual enjoyment (+)d | 47.2 (28.2) | 44.3 (29.3) | 44.4 (31.2) | − 0.10 | − 0.09 |
Female sexual problems (–)d | 37.5 (33.0) | 33.3 (19.2) | 27.8 (25.1) | − 0.16 | 0.33 |